Atlas Trials

A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients With Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutations

Clinical trial NCT07361237 · RECRUITING

Trial details

NCT number
NCT07361237
Sponsor
Tongji University
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
NSCLC (Advanced Non-small Cell Lung Cancer)
Start date
2025-12-30
Primary completion
2028-12-31
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.